Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Dermatology

Free Subscription Articles published in Cancer Lett Retrieve available abstracts of 87 articles: HTML format

Single Articles

September 2025
1. LIU K, Hoover AR, Sun Y, Valerio TI, et al
   Anti-tumor effects on tumor-infiltrating natural killer cells by localized ablative immunotherapy and immune checkpoint inhibitors: An integrated and comparative study using scRNAseq analysis.
   Cancer Lett. 2025;627:217825.
   PubMed     Abstract available
   
   
   July 2025
2. RUPP B, Nagpal N, Thanasiu B, Tuck K, et al
   Multiplex characterization of circulating tumor cells from ductal carcinoma in situ patients suggests early tumor dissemination.
   Cancer Lett. 2025;623:217703.
   PubMed     Abstract available
   
   
   June 2025
3. HAYKAL MM, Rodrigues-Ferreira S, El Botty R, Sourd L, et al
   Targeting WEE1 kinase as a therapeutic strategy in ATIP3-deficient breast cancers.
   Cancer Lett. 2025;620:217665.
   PubMed     Abstract available
   
   
   
4. WANG W, Yang H, Passang T, Li Y, et al
   Targeting the VIP-VPAC Pathway in Melanoma Models Inhibits Tumor Growth and Liver Metastasis.
   Cancer Lett. 2025 Jun 5:217855. doi: 10.1016/j.canlet.2025.217855.
   PubMed     Abstract available
   
   
   May 2025
5. WU R, Yu S, Bi A, Li Y, et al
   Therapeutic targeting of circTNK2 with nanoparticles restores tamoxifen sensitivity and enhances NK cell-mediated immunity in ER-positive breast cancer.
   Cancer Lett. 2025 May 24:217823. doi: 10.1016/j.canlet.2025.217823.
   PubMed     Abstract available
   
   
   
6. ELAYAPILLAI SP, Dogra S, Hladik C, Lausen J, et al
   Preferential Release of microRNAs via Extracellular Vesicles is Associated with Ductal Carcinoma In Situ to Invasive Breast Cancer Progression.
   Cancer Lett. 2025 May 17:217794. doi: 10.1016/j.canlet.2025.217794.
   PubMed     Abstract available
   
   
   
7. ZUO WJ, Ma LX, Wang ZH, Cao XC, et al
   Efficacy and safety of inetetamab plus pertuzumab and nab-paclitaxel as neoadjuvant therapy for HER2+ breast cancer: A single-arm multicenter phase II clinical trial.
   Cancer Lett. 2025 May 10:217785. doi: 10.1016/j.canlet.2025.217785.
   PubMed     Abstract available
   
   
   
8. LIU S, Chen H, Gagea M, Federico L, et al
   ADAMs contribute to triple negative breast cancer via mTORC1 pathway: targeting ADAM-mTOR axis improves efficacy.
   Cancer Lett. 2025 May 6:217775. doi: 10.1016/j.canlet.2025.217775.
   PubMed     Abstract available
   
   
   
9. JIANG C, Qian Y, Bai X, Li S, et al
   SLC7A5/E2F1/PTBP1/PKM2 axis mediates progression and therapy effect of triple-negative breast cancer through the crosstalk of amino acid metabolism and glycolysis pathway.
   Cancer Lett. 2025;617:217612.
   PubMed     Abstract available
   
   
   April 2025
10. GRIMSLEY HE, Antczak M, Reddin IG, Weiler N, et al
    Using a novel panel of drug-resistant triple-negative breast cancer cell lines to identify candidate therapeutic targets and biomarkers.
    Cancer Lett. 2025 Apr 27:217754. doi: 10.1016/j.canlet.2025.217754.
    PubMed     Abstract available
    
    
    
11. TANG R, Xu X, Yang W, Yu W, et al
    Corrigendum to "MED27 promotes melanoma growth by targeting AKT/MAPK and NF/kappaB/iNOS signaling pathway" [Cancer Lett. 373(1) (2016) 77-87 PMID 26797421].
    Cancer Lett. 2025;623:217717.
    PubMed    
    
    
    
12. XIE Y, Xie J, Huang G, Zhang J, et al
    Isoliquiritigenin reduces brain metastasis by circNAV3-ST6GALNAC5-EGFR axis in triple negative breast cancer.
    Cancer Lett. 2025 Apr 21:217734. doi: 10.1016/j.canlet.2025.217734.
    PubMed     Abstract available
    
    
    
13. TIAN H, Chen Y, Dong X, Fan X, et al
    The m(6)A hypermethylation-induced PIR overexpression regulates H3K4me3 and promotes Tumorigenesis of Uveal Melanoma.
    Cancer Lett. 2025 Apr 17:217729. doi: 10.1016/j.canlet.2025.217729.
    PubMed     Abstract available
    
    
    
14. KUNDU M, Greer YE, Lobanov A, Ridnour L, et al
    TRAIL induces cytokine production via the NFkB2 pathway promoting neutrophil chemotaxis and neutrophil-mediated immune-suppression in triple negative breast cancer cells.
    Cancer Lett. 2025;620:217692.
    PubMed     Abstract available
    
    
    March 2025
15. LI H, Chatla S, Liu X, Tian Z, et al
    ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination.
    Cancer Lett. 2025;613:217505.
    PubMed     Abstract available
    
    
    
16. UEMOTO Y, Lin CA, Wang B, Ye D, et al
    Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations.
    Cancer Lett. 2025;619:217668.
    PubMed     Abstract available
    
    
    
17. HOSSAIN SM, Gimenez G, Stockwell P, Weeks R, et al
    Pre-treatment DNA methylome and transcriptome profiles correlate with melanoma response to anti-PD1 immunotherapy.
    Cancer Lett. 2025 Mar 13:217638. doi: 10.1016/j.canlet.2025.217638.
    PubMed     Abstract available
    
    
    
18. WANG Z, He K, Liu M, Lv W, et al
    Enhanced mitochondrial biogenesis facilitates the development of cutaneous squamous cell carcinoma.
    Cancer Lett. 2025 Mar 10:217623. doi: 10.1016/j.canlet.2025.217623.
    PubMed     Abstract available
    
    
    
19. YOU X, Hu X, Sun Z, Xu W, et al
    Dual targeting PPARalpha and NPC1L1 metabolic vulnerabilities blocks tumorigenesis.
    Cancer Lett. 2025;612:217493.
    PubMed     Abstract available
    
    
    
20. GILON-ZALTSMAN O, Weidenfeld-Barenboim K, Samara H, Feuermann Y, et al
    Targeting dormant disseminated tumor cells and their permissive niche by pro-resolving mediators derived from resolution-phase macrophages.
    Cancer Lett. 2025;612:217468.
    PubMed     Abstract available
    
    
    February 2025
21. MARRANCI A, Maresca L, Lodovichi S, Luserna di Rora AG, et al
    PARP1 in Melanoma: Mechanistic Insights and Implications for Basic and Clinical Research.
    Cancer Lett. 2025 Feb 28:217599. doi: 10.1016/j.canlet.2025.217599.
    PubMed     Abstract available
    
    
    
22. ZENG Z, Yi Z, Xu B
    The biological and technical challenges facing utilizing circulating tumor DNA in non-metastatic breast cancer patients.
    Cancer Lett. 2025 Feb 19:217574. doi: 10.1016/j.canlet.2025.217574.
    PubMed     Abstract available
    
    
    
23. CHEN H, Lin L, Qiao Z, Pei Y, et al
    YTHDF3 drives tumor growth and metastasis by recruiting eIF4B to promote Notch2 translation in breast cancer.
    Cancer Lett. 2025;614:217534.
    PubMed     Abstract available
    
    
    
24. URZI O, Olofsson Bagge R, Crescitelli R
    Extracellular vesicles in uveal melanoma - biological roles and diagnostic value.
    Cancer Lett. 2025 Feb 4:217531. doi: 10.1016/j.canlet.2025.217531.
    PubMed     Abstract available
    
    
    January 2025
25. ZHANG R, Jiang WJ, Zhao S, Kang LJ, et al
    FOXF2 expression triggered by endocrine therapy orchestrates therapeutic resistance through reorganization of chromatin architecture in breast cancer.
    Cancer Lett. 2025 Jan 17:217463. doi: 10.1016/j.canlet.2025.217463.
    PubMed     Abstract available
    
    
    
26. TAN N, Xia C, Yan X, Cao M, et al
    Extending breast cancer screening beyond age 45-64 years in China: a cost-effectiveness analysis.
    Cancer Lett. 2025 Jan 13:217457. doi: 10.1016/j.canlet.2025.217457.
    PubMed     Abstract available
    
    
    November 2024
27. MUGHAL MJ, Zhang Y, Li Z, Zhou S, et al
    TFAP2C-DDR1 Axis Regulates Resistance to CDK4/6 Inhibitor in Breast Cancer.
    Cancer Lett. 2024 Nov 25:217356. doi: 10.1016/j.canlet.2024.217356.
    PubMed     Abstract available
    
    
    
28. GERRATANA L, Davis AA, Foffano L, Reduzzi C, et al
    Integrating Machine Learning-Predicted Circulating Tumor Cells (CTCs) and circulating tumor DNA (ctDNA) in Metastatic Breast Cancer: a proof of principle study on endocrine resistance profiling.
    Cancer Lett. 2024 Nov 20:217325. doi: 10.1016/j.canlet.2024.217325.
    PubMed     Abstract available
    
    
    
29. TRAPPETTI V, Fernandez-Palomo C, Arora P, Potez M, et al
    "Towards melanoma in situ vaccination with multiple ultra-narrow X-ray beams".
    Cancer Lett. 2024 Nov 13:217326. doi: 10.1016/j.canlet.2024.217326.
    PubMed     Abstract available
    
    
    
30. LIU K, Hoover AR, Wang L, Sun Y, et al
    Localized ablative immunotherapy enhances antitumor immunity by modulating the transcriptome of tumor-infiltrating Gamma delta T cells.
    Cancer Lett. 2024;604:217267.
    PubMed     Abstract available
    
    
    October 2024
31. BHATTARAI PY, Kim G, Lim SC, Choi HS, et al
    METTL3-STAT5B interaction facilitates the co-transcriptional m(6)A modification of mRNA to promote breast tumorigenesis.
    Cancer Lett. 2024;603:217215.
    PubMed     Abstract available
    
    
    September 2024
32. YU L, Wei W, Lv J, Lu Y, et al
    FABP4-mediated lipid metabolism promotes TNBC progression and breast cancer stem cell activity.
    Cancer Lett. 2024 Sep 19:217271. doi: 10.1016/j.canlet.2024.217271.
    PubMed     Abstract available
    
    
    
33. WINNARD PT JR, Vesuna F, Bol GM, Gabrielson KL, et al
    Targeting RNA Helicase DDX3X with a Small Molecule Inhibitor for Breast Cancer Bone Metastasis Treatment.
    Cancer Lett. 2024 Sep 19:217260. doi: 10.1016/j.canlet.2024.217260.
    PubMed     Abstract available
    
    
    
34. LIU X, Ma Z, Jing X, Wang G, et al
    The deubiquitinase OTUD5 stabilizes SLC7A11 to promote progression and reduce paclitaxel sensitivity in triple-negative breast cancer.
    Cancer Lett. 2024 Sep 12:217232. doi: 10.1016/j.canlet.2024.217232.
    PubMed     Abstract available
    
    
    
35. CHICA-PARRADO MR, Kim GM, Uemoto Y, Napolitano F, et al
    Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer.
    Cancer Lett. 2024 Sep 5:217219. doi: 10.1016/j.canlet.2024.217219.
    PubMed     Abstract available
    
    
    
36. ZHANG Z, Zhao M, Wang Q, Wang X, et al
    Forkhead box protein FOXK1 disrupts the circadian rhythm to promote breast tumorigenesis in response to insulin resistance.
    Cancer Lett. 2024;599:217147.
    PubMed     Abstract available
    
    
    August 2024
37. GAO Q, Li N, Pan Y, Chu P, et al
    Hepatocyte growth factor promotes melanoma metastasis through ubiquitin-specific peptidase 22-mediated integrins upregulation.
    Cancer Lett. 2024 Aug 31:217196. doi: 10.1016/j.canlet.2024.217196.
    PubMed     Abstract available
    
    
    
38. SRIVASTAVA P, Jha S, Singh SK, Vyas H, et al
    Protease activated receptor-1 regulates mixed lineage kinase-3 to drive triple-negative breast cancer tumorigenesis.
    Cancer Lett. 2024;603:217200.
    PubMed     Abstract available
    
    
    
39. MA Y, Zhang H, Shen X, Yang X, et al
    Aptamer functionalized hypoxia-potentiating agent and hypoxia-inducible factor inhibitor combined with hypoxia-activated prodrug for enhanced tumor therapy.
    Cancer Lett. 2024;598:217102.
    PubMed     Abstract available
    
    
    
40. LIU B, Liu Y, Yang S, Ye J, et al
    Enhanced desmosome assembly driven by acquired high-level desmoglein-2 promotes phenotypic plasticity and endocrine resistance in ER(+) breast cancer.
    Cancer Lett. 2024;600:217179.
    PubMed     Abstract available
    
    
    
41. GU T, Vasilatos SN, Yin J, Qin Y, et al
    Restoration of TFPI2 by LSD1 Inhibition Suppresses Tumor Progression and Potentiates Antitumor Immunity in Breast Cancer.
    Cancer Lett. 2024 Aug 16:217182. doi: 10.1016/j.canlet.2024.217182.
    PubMed     Abstract available
    
    
    
42. VIDANA GAMAGE HE, Albright ST, Smith AJ, Farmer R, et al
    Development of NR0B2 as a therapeutic target for the re-education of tumor associated myeloid cells.
    Cancer Lett. 2024;597:217086.
    PubMed     Abstract available
    
    
    
43. VIDANA GAMAGE HE, Shahoei SH, Wang Y, Jacquin E, et al
    NR0B2 re-educates myeloid immune cells to reduce regulatory T cell expansion and progression of breast and other solid tumors.
    Cancer Lett. 2024;597:217042.
    PubMed     Abstract available
    
    
    
44. REGUA AT, Bindal S, Najjar MK, Zhuang C, et al
    Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers.
    Cancer Lett. 2024;597:217023.
    PubMed     Abstract available
    
    
    
45. YANG Y, Hao X, Zhang J, Gao T, et al
    The E3 ligase TRIM22 functions as a tumor suppressor in breast cancer by targeting CCS for proteasomal degradation to inhibit STAT3 signaling.
    Cancer Lett. 2024 Aug 8:217157. doi: 10.1016/j.canlet.2024.217157.
    PubMed     Abstract available
    
    
    
46. FLETCHER K, Cortellini A, Ganta T, Kankaria R, et al
    Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study.
    Cancer Lett. 2024;596:217001.
    PubMed     Abstract available
    
    
    
47. KIM YJ, Lee M, Kim EH, Lee S, et al
    Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: A nationwide retrospective cohort study.
    Cancer Lett. 2024;596:216998.
    PubMed     Abstract available
    
    
    July 2024
48. LI M, Zhang L, Guan T, Huang L, et al
    Energy stress-activated AMPK phosphorylates Snail1 and suppresses its stability and oncogenic function.
    Cancer Lett. 2024;595:216987.
    PubMed     Abstract available
    
    
    
49. LIU Y, Yin S, Lu G, Du Y, et al
    The intersection of the nervous system and breast cancer.
    Cancer Lett. 2024;598:217132.
    PubMed     Abstract available
    
    
    
50. LIU M, Zhao Z, Wang C, Sang S, et al
    Harnessing genetic interactions for prediction of immune checkpoint inhibitors response signature in cancer cells.
    Cancer Lett. 2024;594:216991.
    PubMed     Abstract available
    
    
    
51. ZHANG H, Zhang L, He Y, Jiang D, et al
    PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer.
    Cancer Lett. 2024 Jul 8:217112. doi: 10.1016/j.canlet.2024.217112.
    PubMed     Abstract available
    
    
    
52. FU Z, Zhang L, Chen R, Zhan J, et al
    Biphasic co-detection of melanoma aneuploid tumor cells and tumor endothelial cells in guidance of specifying the field cancerized surgical excision margin and administering immunotherapy.
    Cancer Lett. 2024;598:217099.
    PubMed     Abstract available
    
    
    June 2024
53. LIAO Q, Shi H, Yang J, Ge S, et al
    FTO elicits tumor neovascularization in cancer-associated fibroblasts through eliminating m(6)A modifications of multiple pro-angiogenic factors.
    Cancer Lett. 2024;592:216911.
    PubMed     Abstract available
    
    
    
54. WAN YX, Qi XW, Lian YY, Liu ZY, et al
    Electroacupuncture Facilitates Vascular Normalization by Inhibiting Glyoxalase1 in Endothelial Cells to Attenuate Glycolysis and Angiogenesis in Triple-Negative Breast Cancer.
    Cancer Lett. 2024 Jun 28:217094. doi: 10.1016/j.canlet.2024.217094.
    PubMed     Abstract available
    
    
    
55. YU Y, Cao WM, Cheng F, Shi Z, et al
    FOXK2 amplification promotes breast cancer development and chemoresistance.
    Cancer Lett. 2024 Jun 18:217074. doi: 10.1016/j.canlet.2024.217074.
    PubMed     Abstract available
    
    
    
56. LIU J, Zhai M, Chen Y, Wei Y, et al
    Acetylation-dependent deubiquitinase USP26 stabilizes BAG3 to promote breast cancer progression.
    Cancer Lett. 2024 Jun 14:217005. doi: 10.1016/j.canlet.2024.217005.
    PubMed     Abstract available
    
    
    
57. WANG S, Xu L, Wang D, Zhao S, et al
    YTHDF1 promotes the osteolytic bone metastasis of breast cancer via inducing EZH2 and CDH11 translation.
    Cancer Lett. 2024 Jun 11:217047. doi: 10.1016/j.canlet.2024.217047.
    PubMed     Abstract available
    
    
    
58. LI SY, Zhang N, Zhang H, Wang N, et al
    Deciphering the TCF19/miR-199a-5p/SP1/LOXL2 pathway: Implications for breast cancer metastasis and epithelial-mesenchymal transition.
    Cancer Lett. 2024;597:216995.
    PubMed     Abstract available
    
    
    
59. ANDRIANI L, Ling YX, Yang SY, Zhao Q, et al
    Sideroflexin-1 promotes progression and sensitivity to lapatinib in triple-negative breast cancer by inhibiting the TOLLIP-mediated autophagic degradation of CIP2A.
    Cancer Lett. 2024 Jun 5:217008. doi: 10.1016/j.canlet.2024.217008.
    PubMed     Abstract available
    
    
    
60. OLUWALANA D, Adeleye KL, Krutilina RI, Chen H, et al
    Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancer.
    Cancer Lett. 2024 Jun 5:217011. doi: 10.1016/j.canlet.2024.217011.
    PubMed     Abstract available
    
    
    
61. RIVERA-RAMOS A, Cruz-Hernandez L, Talaveron R, Sanchez-Montero MT, et al
    Galectin-3 depletion tames pro-tumoural microglia and restrains cancer cells growth.
    Cancer Lett. 2024;591:216879.
    PubMed     Abstract available
    
    
    May 2024
62. SONG Y, Ren S, Chen X, Li X, et al
    Inhibition of MFN1 restores tamoxifen-induced apoptosis in resistant cells by disrupting aberrant mitochondrial fusion dynamics.
    Cancer Lett. 2024;590:216847.
    PubMed     Abstract available
    
    
    
63. LV Y, Sun S, Zhang J, Wang C, et al
    Loss of RBM45 inhibits breast cancer progression by reducing the SUMOylation of IRF7 to promote IFNB1 transcription.
    Cancer Lett. 2024 May 24:216988. doi: 10.1016/j.canlet.2024.216988.
    PubMed     Abstract available
    
    
    
64. WANG J, Hirose H, Du G, Chong K, et al
    Corrigendum to "P-REX1 amplification promotes progression of cutaneous melanomavia the PAK1/P38/MMP-2 pathway" [Cancer Lett. 407 (2017) 66-75].
    Cancer Lett. 2024 May 23:216966. doi: 10.1016/j.canlet.2024.216966.
    PubMed    
    
    
    
65. LIN Z, Chen L, Wang Y, Zhang T, et al
    Improving Ultrasound Diagnostic Precision for Breast Cancer and Adenosis with Modality-Specific Enhancement (MSE) - Breast Net.
    Cancer Lett. 2024 May 23:216977. doi: 10.1016/j.canlet.2024.216977.
    PubMed     Abstract available
    
    
    
66. BELLI S, Esposito D, Ascione CM, Messina F, et al
    EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.
    Cancer Lett. 2024 May 22:216968. doi: 10.1016/j.canlet.2024.216968.
    PubMed     Abstract available
    
    
    April 2024
67. ZHANG Y, Tan Y, Yuan J, Tang H, et al
    circLIFR-007 reduces liver metastasis via promoting hnRNPA1 nuclear export and YAP phosphorylation in breast cancer.
    Cancer Lett. 2024;592:216907.
    PubMed     Abstract available
    
    
    
68. JIA Y, Zhang F, Meng X, Andreev D, et al
    Osteocytes support bone metastasis of melanoma cells by CXCL5.
    Cancer Lett. 2024 Apr 6:216866. doi: 10.1016/j.canlet.2024.216866.
    PubMed     Abstract available
    
    
    
69. WANG L, Liu X, Han Y, Tsai HI, et al
    TRAF6 enhances PD-L1 expression through YAP1-TFCP2 signaling in melanoma.
    Cancer Lett. 2024 Apr 5:216861. doi: 10.1016/j.canlet.2024.216861.
    PubMed     Abstract available
    
    
    
70. LI K, Lin H, Liu A, Qiu C, et al
    SOD1-high fibroblasts derived exosomal miR-3960 promotes cisplatin resistance in triple-negative breast cancer by suppressing BRSK2-mediated phosphorylation of PIMREG.
    Cancer Lett. 2024;590:216842.
    PubMed     Abstract available
    
    
    
71. WANG J, Fan P, Shen P, Fan C, et al
    XBP1s activates METTL3/METTL14 for ER-phagy and paclitaxel sensitivity regulation in breast cancer.
    Cancer Lett. 2024 Apr 4:216846. doi: 10.1016/j.canlet.2024.216846.
    PubMed     Abstract available
    
    
    
72. ORHAN E, Velazquez C, Tabet I, Fenou L, et al
    CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer.
    Cancer Lett. 2024 Apr 2:216820. doi: 10.1016/j.canlet.2024.216820.
    PubMed     Abstract available
    
    
    
73. BULLOCK KK, Shattuck-Brandt R, Scalise C, Luo W, et al
    Endogenous pAKT activity is associated with response to AKT inhibition alone and in combination with immune checkpoint inhibition in murine models of TNBC.
    Cancer Lett. 2024;586:216681.
    PubMed     Abstract available
    
    
    March 2024
74. YANG Z, Chen H, Yin S, Mo H, et al
    PGR-KITLG signaling drives a tumor-mast cell regulatory feedback to modulate apoptosis of breast cancer cells.
    Cancer Lett. 2024 Mar 29:216795. doi: 10.1016/j.canlet.2024.216795.
    PubMed     Abstract available
    
    
    
75. IDRISS MH, Stull CM, Migden MR
    Treatments on the horizon for locally advanced basal cell carcinoma.
    Cancer Lett. 2024;589:216821.
    PubMed     Abstract available
    
    
    
76. JABBARZADEH KABOLI P, Chen HF, Babaeizad A, Roustai Geraylow K, et al
    Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer.
    Cancer Lett. 2024 Mar 8:216780. doi: 10.1016/j.canlet.2024.216780.
    PubMed     Abstract available
    
    
    
77. MADORSKY ROWDO FP, Xiao G, Khramtsova GF, Nguyen J, et al
    Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
    Cancer Lett. 2024;584:216608.
    PubMed     Abstract available
    
    
    February 2024
78. WANG X, Deng X, Hu J, Zheng W, et al
    K48-linked deubiquitination of VGLL4 by USP15 enhances the efficacy of tumor immunotherapy in triple-negative breast cancer.
    Cancer Lett. 2024 Feb 29:216764. doi: 10.1016/j.canlet.2024.216764.
    PubMed     Abstract available
    
    
    
79. SUN J, Du R, Li X, Liu C, et al
    CD63(+) cancer-associated fibroblasts confer CDK4/6 inhibitor resistance to breast cancer cells by exosomal miR-20.
    Cancer Lett. 2024 Feb 23:216747. doi: 10.1016/j.canlet.2024.216747.
    PubMed     Abstract available
    
    
    
80. HAN BY, Chen C, Luo H, Lin CJ, et al
    Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-Low Breast Cancer.
    Cancer Lett. 2024 Feb 23:216763. doi: 10.1016/j.canlet.2024.216763.
    PubMed     Abstract available
    
    
    
81. MURTHY D, Dutta D, Attri KS, Samanta T, et al
    CD24 negativity reprograms mitochondrial metabolism to PPARalpha and NF-kappaB-driven fatty acid beta-oxidation in triple-negative breast cancer.
    Cancer Lett. 2024 Feb 17:216724. doi: 10.1016/j.canlet.2024.216724.
    PubMed     Abstract available
    
    
    
82. XIONG H, Zhai Y, Meng Y, Wu Z, et al
    Acidosis activates breast cancer ferroptosis through ZFAND5/SLC3A2 signaling axis and elicits M1 macrophage polarization.
    Cancer Lett. 2024 Feb 13:216732. doi: 10.1016/j.canlet.2024.216732.
    PubMed     Abstract available
    
    
    
83. BAHREYNI A, Mohamud Y, Luo H
    Oncolytic virus-based combination therapy in breast cancer.
    Cancer Lett. 2024 Feb 1:216634. doi: 10.1016/j.canlet.2024.216634.
    PubMed     Abstract available
    
    
    
84. TAN Z, Boyapati K, Tressler CM, Jenkinson N, et al
    Glutamine transporter SLC38A3 promotes breast cancer metastasis via Gsk3beta/beta-catenin/EMT pathway.
    Cancer Lett. 2024 Feb 1:216653. doi: 10.1016/j.canlet.2024.216653.
    PubMed     Abstract available
    
    
    January 2024
85. CHEN SY, Zhang FL, Zhang YL, Liao L, et al
    Spermatid perinuclear RNA-binding protein promotes UBR5-mediated proteolysis of Dicer to accelerate triple-negative breast cancer progression.
    Cancer Lett. 2024 Jan 25:216672. doi: 10.1016/j.canlet.2024.216672.
    PubMed     Abstract available
    
    
    
86. LIU C, Qian X, Yu C, Xia X, et al
    Inhibition of ATM promotes PD-L1 expression by activating JNK/c-Jun/TNF-alpha signaling axis in triple-negative breast cancer.
    Cancer Lett. 2024 Jan 24:216642. doi: 10.1016/j.canlet.2024.216642.
    PubMed     Abstract available
    
    
    
87. JIA F, Sun S, Li J, Wang W, et al
    Neoadjuvant chemotherapy-induced remodeling of human hormonal receptor-positive breast cancer revealed by single-cell RNA sequencing.
    Cancer Lett. 2024 Jan 22:216656. doi: 10.1016/j.canlet.2024.216656.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Dermatology is free of charge.